Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$0.66.

  • 60 Degrees Pharmaceuticals' EPS (Basic) rose 8580.65% to -$0.66 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.28, marking a year-over-year increase of 9963.41%. This contributed to the annual value of -$18.55 for FY2024, which is 6866.32% up from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported EPS (Basic) of -$0.66 as of Q3 2025, which was up 8580.65% from -$1.18 recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' 5-year EPS (Basic) high stood at $9.13 for Q3 2023, and its period low was -$31.32 during Q4 2023.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median EPS (Basic) value was -$1.15 (recorded in 2023), while the average stood at -$5.33.
  • The largest annual percentage gain for 60 Degrees Pharmaceuticals' EPS (Basic) in the last 5 years was 159672.13% (2023), contrasted with its biggest fall of 437647.05% (2023).
  • 60 Degrees Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.7 in 2022, then tumbled by 4376.47% to -$31.32 in 2023, then skyrocketed by 84.69% to -$4.8 in 2024, then surged by 86.24% to -$0.66 in 2025.
  • Its last three reported values are -$0.66 in Q3 2025, -$1.18 for Q2 2025, and -$1.56 during Q1 2025.